Overcoming antimicrobial resistance by targeting resistance mechanisms

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 3, 2001, Pages 283-294

  Poole, K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CHELATING AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; COLISTIN; DOXYCYCLINE; EDETIC ACID; ERYTHROMYCIN; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LINCOSAMIDE; MACROLIDE; NORFLOXACIN; PEPTIDE; POLYMYXIN B NONAPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RIFAMPICIN; SITAFLOXACIN; STREPTOGRAMIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL MUTATION; CELL MEMBRANE PERMEABILITY; DRUG CROSS REACTIVITY; DRUG INACTIVATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME MODIFICATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; NONHUMAN; PROTEIN TRANSPORT; REVIEW; RNA METHYLATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 0035098206     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011775514     Document Type: Review

References (164)

1. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus
2. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model
3. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): A new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens
4. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides
5. 7-Hydroxytropolone: An inhibitor of aminoglycoside-2″-O-adenylyltransferase
6. A new chloramphenicol and florfenicol resistance gene flanked by two integron structures in Salmonella typhimurium DT104
7. Effect of conalbumin on the activity of Syn 2190, a 1, 5 dihydroxy-4-pyridon monobactam inhibitor of AmpC β-lactamases
8. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: Influence of resistance mechanisms and methodological factors
9. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
10. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin
11. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
12. Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
13. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins
14. β-Lactamases of increasing clinical importance
15. How β-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention
16. The synthesis and evaluation of 2-substituted-7-(alkylidene)cephalosporin sulfones as β-lactamase inhibitors
17. The synthesis and evaluation of 3-substituted-7-(alkylidene)-cephalosporin sulfones as β-lactamase inhibitors
18. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa
19. Vancomycin-resistant enterococci
20. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics
21. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications
22. Activity of cefepime and other β-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae
23. Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance
24. Assays to detect and characterize synthetic agents that inhibit the ErmC methyltransferase
25. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes
26. Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae
27. Bacterial resistance mechanisms as therapeutic targets
28. Crystal structure of the IMP-1 metallo β-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: Binding determinants of a potent, broad-spectrum inhibitor
29. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors
30. Antipneumococcal activity of ABT-773 compared to those of 10 other agents
31. Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens
32. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
33. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
34. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
35. Unanticipated inhibition of the metallo-β-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): A crystallographic study at 1.85-A resolution
36. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
37. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment
38. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria
39. Modulation of erm methyltransferase activity by peptides derived from phage display
40. Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis
41. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors
42. An antibiotic cloaked by its own resistance enzyme
43. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis
44. β-Lactam resistance in Streptococcus pneumoniae: Penicillin-binding proteins and non-penicillin-binding proteins
45. Alterations in outer membrane permeability
46. The bacterial outer membrane as a drug barrier
47. Antibacterial peptides and the outer membranes of Gram-negative bacilli
48. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane
49. Roles of porin and β-lactamase in β-lactam resistance of Pseudomonas aeruginosa
50. Design and synthesis of mimics of S-adenosyl-L-homocysteine as potential inhibitors of erythromycin methyltransferases
51. Structure-based design of β-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams
52. Confronting the problem of increasing antibiotic resistance
53. Mechanisms of action and resistance of older and newer fluoroquinolones
54. The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa
55. Design of potent β-lactamase inhibitors by phage display of β-lactamase inhibitory protein
56. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus
57. Mechanisms and frequency of resistance to moxifloxacin in comparison with ciprofloxacin in Staphylococcus aureus
58. New quinolone resistance in clinical isolates of Pseudomonas aeruginosa
59. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa
60. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
61. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
62. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
63. Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance
64. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
65. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogrammin antibiotics in bacteria
66. Clinical impact of antibiotic resistance
67. Reversing tetracycline resistance. A renaissance for the tetracycline family of antibiotics
68. β-Lactamase inhibitors are substrates of the multidrug efflux pumps of Pseudomonas aeruginosa
69. Interplay between the MexAB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa
70. β-Lactamase-mediated resistance and opportunities for its control
71. Epidemiology of antibiotic resistance
72. Potentiation of β-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases
73. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa
74. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy
75. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli
76. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria
77. β-Lactamase inhibitors: Agents to overcome bacterial resistance
78. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine
79. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus
80. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus
81. Recent advances in the chemistry of β-lactam compounds as selected active-site serine β-lactamase inhibitors
82. A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus
83. Contributions of the AmpC β-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to β-lactams
84. + antiport in Cmr (MdfA) system of Escherichia coli and properties of the antiporter
85. An inhibitor of chloramphenicol acetyltransferase produced by Streptomyces
86. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei
87. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
88. Inhibition of the broad spectrum nonmetallocarbapenamase of class A (NMC-A) β-lactamase from Enterobacter cloacae by monocyclic β-lactams
89. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates
90. O-Acetyltransferases for chloramphenicol and other natural products
91. Macrolide esterase-producing Escherichia coli clinically isolated in Japan
92. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein
93. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines
94. Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria
95. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 β-lactamase
96. Prevention of drug access to bacterial targets: Permeability barriers and active efflux
97. The role of outer membrane and efflux pumps in the resistance of Gram-negative bacteria. Can we improve drug access?
98. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump
99. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae
100. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
101. Inhibition of metallo-β-lactamases by a series of thiol ester derivatives of mercaptophenylacetic acid
102. Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol ester derivatives
103. β-Lactamase epidemiology and the utility of established and novel β-lactamase inhibitors
104. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
105. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
106. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa
107. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification
108. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria
109. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria
110. The complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamase
111. Antimicrobial potentiation approaches: Targets and inhibitors
112. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin
113. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine
114. Design, synthesis, and evaluation of 2 β-alkenyl penam sulfone acids as inhibitors of β-lactamases
115. Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution
116. Loss of individual electrostatic interactions between aminoglycoside antibiotics and resistance enzymes as an effective means to overcoming bacterial drug resistance
117. The use of neamine as a molecular template: Inactivation of bacterial antibiotic resistance enzyme aminoglycoside 3′-phosphotransferase type IIa
118. Mechanism-based inactivation of bacterial aminoglycoside 3′-phosphotransferases
119. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin
120. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family
121. Glycerol monolaurate inhibits induction of vancomycin resistance in Enterococcus faecalis
122. The acr AB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump
123. Dipolar cycloaddition of novel 6-(nitrileoxidomethyl) penam sulfone: An efficient route to a new class of β-lactamase inhibitors
124. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
125. In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus
126. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals
127. Biological properties of structurally related α-helical cationic antimicrobial peptides
128. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
129. A novel glycylcycline, 9-(N, N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter
130. Contribution of the MexAB-OprM multidrug efflux system to the β-lactam resistance of penicillin-binding protein and β-lactamase-derepressed mutants of Pseudomonas aeruginosa
131. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor
132. Salmonella typhimurium and Escherichia coli mutants with increased outer membrane permeability to hydrophobic compounds
133. Recent developments in tetracycline antibiotics
134. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
135. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus
136. Mechanisms of 4-quinolone resistant and methicillin resistant Staphylococcus aureus isolates from Japan
137. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics
138. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines
139. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: Perspectives and future directions
140. Version 2000: The new β-lactamases of gram-negative bacteria at the dawn of the new millenium
141. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-β-lactamase
142. Agents that increase the permeability of the outer membrane
143. Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium
144. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria
145. Outer membrane permeability barrier in Escherichia coli mutants that are defective in the late acyltransferases of lipid A biosynthesis
146. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria
147. 5-Epi-Sisomicin and 5-epi-Gentamicin B: Substrates for amino-glycoside-modifying enzymes that retain activity against aminoglycoside-resistant bacteria
148. The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility
149. Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamase inhibitors
150. Hydroxamate inhibitors of Aeromonas hydrophila AE036 metallo-β-lactamase
151. Erythromycin resistance by ribosome modification
152. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase
153. Aminoglycoside-modifying enzymes
154. Resisting resistance: New chemical strategies for battling superbugs
155. Amino-glycoside antibiotics. Structures, functions, and resistance
156. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane
157. Phosphinate analogs of D-, D-dipeptides: Slow-binding inhibition and proteolysis protection of VanX, a D-, D-dipeptidase required for vancomycin resistance in Enterococcus faecium
158. Dithiol compounds: Potent time-dependent inhibitors of VanX, a zinc-dependent D, D-dipeptidase required for vancomycin resistance in Enterococcus faecium
159. Overexpression, purification, and characterization of VanX, a D-, D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147
160. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
161. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa
162. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations
163. Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones
164. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa